Indy Star interviewed Thomas F. Imperiale, M.D., about his study published in the New England Journal of Medicine. This next generation multi-target stool DNA colorectal cancer screening test detects 94 percent of colorectal cancers and has the best performance for detection of both colorectal cancer and advanced precancerous polyps of any noninvasive colorectal cancer screening test.
-
Research
- Experts
In The News
View AllAP News features LOINC
LOINC, developed and maintained by the Regenstrief Institute, was featured by AP...
Influence
View AllRegenstrief’s legacy with the National Library of Medicine continues
Peter J. Embí, M.D., M.S., former president and CEO of...
- About
Regenstrief is dedicated to pioneering transformative solutions for a healthier world.
- The Latest
- Collaboration
Generating Evidence Across the Full Arc of Disease
Regenstrief Institute x Merck The Question Clinical trials establish whether...
Evaluating AI-Enabled Trial Screening in Real-World Oncology Workflows
Regenstrief, Triomics and Indiana University Health, supported by an independent...
- Experts



